| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_227129d9357b7571736157c67b1a39fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a14c99090d4b8a45d0c5bae727a8d370 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-93 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-866 |
| filingDate |
2013-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8d7a593af888b0e7d9843d9eaad60bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b92ef880a796f71c6439aa97cfe884a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06c344e80f105d908cf484fb0e472dca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a54f845e8378539fb97713dc92e569ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f52e53a6305c4d974649eff1aefa0611
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06f51fe5bc352be67428703b68937c04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e61599aa8688c007ce8de19667e6addb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fd310bee20187070d7b8574588194d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0af7eb2204422f18042586dd760f0b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ceae1698f1b959bfd1d02483652e81a0 |
| publicationDate |
2015-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-103555746-B |
| titleOfInvention |
Recombinant porcine circovirus type 2 virus-like particle, and preparation method and application thereof |
| abstract |
The invention discloses a recombinant porcine circovirus type 2 (PCV2) virus-like particle (VLP). The VLP is prepared by connecting a protein transduction domain originated from HSV-1VP22 with an antigen Cap gene needed for formation of PCV2 hollow capsid protein by using an SOE-PCR method, then carrying out cloning to a baculovirus transporter so as to obtain a homologous recombinant vector, carrying out encapsulation so as to produce recombinant baculovirus containing PCV2Cap protein and the protein transduction domain of HSV-1VP22, infecting an insect cell and expressing recombinant Cap-VP22 protein in which PCV2Cap protein and the protein transduction domain of HSV-1VP22 are fused. According to results of research, the VLP prepared in the invention can be individually used or used with adjuvant for inoculation to an animal and effectively stimulates generation of a specific antibody to PCV2. Thus, the VLP provided by the invention can be applied to development of a novel high-efficiency PCV2 subunit vaccine with a good immune effect. |
| priorityDate |
2013-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |